Maj Soueidan on X
Tom Patton’s medical-device CEO record is framed as a missed opportunity for KRMD during its board battle.
NASDAQ
KRMD
4 articles
$149M Market cap · 2026-08-25
Tom Patton’s medical-device CEO record is framed as a missed opportunity for KRMD during its board battle.
KRMD's CEO departs after building its pharma-partner platform, infusion products and modest profitability; the company is described as a recurring-revenue acquisition candidate.
Highly likely we’ll soon see some insider purchases at $KRMD - given today’s drop on Q2 earnings. https://t.co/q3GM4y5V4P
FTEK, OESX and KRMD earnings calls will address data center pipelines, one-time project awards and new-product adoption.